Mon panier

Human IGF-II Protein, Fc Tag

Avis des utilisateurs
Numéro de produit/spécification
Prix
Qté
IG2-H4260-100ug
$225.00
IG2-H4260-1mg (500ug X 2)
$1595.00
ETA of in-stock products:2 business days
Total des articles Montant du produit$ 0

Détails du produit

  • Synonyms

    IGF2, C11orf43, FLJ22066, FLJ44734, IGF-II, PP9974

  • Source

    Human IGF-II, Fc Tag (IG2-H4260) is expressed from human 293 cells (HEK293). It contains AA Ala 25 - Glu 91 (Accession # P01344-1).

    Request for sequence
  • Molecular Characterization

    IGF-II Structure

    Other Tags and Version Biotin & Other Labeled Version

    This protein carries a human IgG1 Fc tag at the N-terminus.

    The protein has a calculated MW of 34.4 kDa. The protein migrates as 35-38 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

  • Endotoxin

    Less than 1.0 EU per μg by the LAL method / rFC method.

  • Purity

    >90% as determined by SDS-PAGE.

  • Formulation

    Lyophilized from 0.22 μm filtered solution in 50 mM Tris, 100 mM Glycine, pH7.5 with trehalose as protectant.

    Contact us for customized product form or formulation.

  • Reconstitution

    Please see Certificate of Analysis for specific instructions.

    For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

  • Storage

    For long term storage, the product should be stored at lyophilized state at -20°C or lower.

    Please avoid repeated freeze-thaw cycles.

    This product is stable after storage at:

    1. -20°C to -70°C for 12 months in lyophilized state;
    2. -70°C for 3 months under sterile conditions after reconstitution.
  • ACRO Quality Management System

    1. QMS(ISO, GMP)
    2. Quality Advantages
    3. Quality Control Process

Les clients ont également consulté

Affichage des données

  • SDS-PAGE

    IGF-II SDS-PAGE

    Human IGF-II, Fc Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 90%.

  • Bioactivity-ELISA

     IGF-II ELISA

    Immobilized Human IGFBP-3, His Tag (Cat. No. IG3-H52H9) at 0.5 μg/mL (100 μL/well) can bind Human IGF-II, Fc Tag (Cat. No. IG2-H4260) with a linear range of 1.2-39 ng/mL (QC tested).

    Protocol
  •  IGF-II ELISA

    Immobilized Human IGF-II, Fc Tag (Cat. No. IG2-H4260) at 5 μg/mL (100 μL/well) can bind Biotinylated Human IGFBP-4 Protein, His,Avitag (Cat. No. IG4-H82E3) with a linear range of 2-40 ng/mL (Routinely tested).

    Protocol

Avis des utilisateurs
Publier un commentaire

Introduction de fond

Insulin-like growth factor 2 (IGF-2) is also known as Somatomedin-A, IGF-II, PP9974, and is one of three protein hormones that share structural similarity to insulin. IGF-2 exerts its effects by binding to the IGF-1 receptor. IGF2 may also bind to the IGF-2 receptor (also called the cation-independent mannose 6-phosphate receptor), which acts as a signalling antagonist; that is, to prevent IGF2 responses. The major role of IGF2 is as a growth promoting hormone during gestation. In the process of Folliculogenesis, IGF2 is created by Theca cells to act in an autocrine manner on the theca cells themselves, and in a paracrine manner on Granulosa cells in the ovary. IGF2 promotes granulosa cell proliferation during the follicular phase of the menstrual cycle, acting alongside Follicle Stimulating Hormone (FSH). After ovulation has occurred, IGF-2 promotes progesterone secretion during the luteal phase of the menstrual cycle together with Luteinizing Hormone (LH). Thus, IGF2 acts as a Co-hormone together with both FSH and LH. IGF-2 may play a key role in memory and could potentially be used to treat Alzheimer's Disease. It is sometimes produced in excess in islet cell tumours, causing hypoglycemia. Doege-Potter syndrome is a paraneoplastic syndrome in which hypoglycemia is associated with the presence of one or more non-islet fibrous tumors in the pleural cavity. has been shown to interact with IGFBP3 and Transferrin.

Progrès de frontière

 
Progrès du développement médicamenteux
  • Nom anglais:

    Insulin-like growth factor II

  • Catégorie:

  • Nombre de médicaments répertoriés:

    0 Détails

  • Nombre de médicaments cliniques:

    1 Détails

  • Étape de développement la plus élevée:

    Phase 2 Clinical

Drug Candidate Licensing
More
  • Informations de base sur le produit
  • Détails du produit
  • Les clients ont également consulté
  • Affichage des données
  • Avis des utilisateurs
  • Contexte